

Title (en)
TOPICAL FORMULATIONS HAVING CANNABINOID

Title (de)
TOPIISCHE FORMULIERUNGEN MIT CANNABINOID

Title (fr)
FORMULATIONS TOPIQUES COMPRENANT UN CANNABINOÏDE

Publication
EP 3906025 A1 20211110 (EN)

Application
EP 20736215 A 20200103

Priority

- US 201962788494 P 20190104
- US 2020012187 W 20200103

Abstract (en)
[origin: WO2020142692A1] Disclosed are cannabinoid formulations and methods of use associated therewith. Specifically, disclosed are topical or transdermal formulations having a cannabinoid in combination with a phyto-compound excipient that facilitates absorption and bioavailability of the cannabinoid.

IPC 8 full level
A61K 31/352 (2006.01); **A61K 9/00** (2006.01); **A61K 31/01** (2006.01); **A61K 31/165** (2006.01); **A61K 31/36** (2006.01); **A61K 36/185** (2006.01); **A61K 36/67** (2006.01); **A61K 36/81** (2006.01); **A61K 38/48** (2006.01); **A61M 15/00** (2006.01); **A61P 17/00** (2006.01); **A61P 25/00** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP)
A61K 9/0014 (2013.01); **A61K 9/124** (2013.01); **A61K 31/05** (2013.01); **A61K 31/352** (2013.01); **A61K 36/185** (2013.01); **A61K 36/67** (2013.01); **A61K 36/81** (2013.01); **A61K 38/4873** (2013.01); **A61P 17/00** (2017.12); **A61P 25/00** (2017.12); **A61P 35/00** (2017.12); **C12Y 304/22002** (2013.01); **A61M 11/00** (2013.01); **A61M 2210/04** (2013.01)

C-Set (source: EP)

1. **A61K 36/185 + A61K 2300/00**
2. **A61K 36/67 + A61K 2300/00**
3. **A61K 36/81 + A61K 2300/00**
4. **A61K 38/4873 + A61K 2300/00**
5. **A61K 31/05 + A61K 2300/00**
6. **A61K 31/352 + A61K 2300/00**

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2020142692 A1 20200709; EP 3906025 A1 20211110; EP 3906025 A4 20220921

DOCDB simple family (application)
US 2020012187 W 20200103; EP 20736215 A 20200103